Tumor-targeting intravenous lipid emulsion of paclitaxel: Characteristics, stability, toxicity, and toxicokinetics

Jun Ye; Lin Li; Jiye Yin; Hongliang Wang; Renjie Li; Yanfang Yang; Yongbiao Guan; Xuejun Xia; Yuling Liu

doi:10.1016/j.jpha.2022.08.002

Volume 12 Issue 6

Dec. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2022 > 12(6): 901-912

Jun Ye, Lin Li, Jiye Yin, Hongliang Wang, Renjie Li, Yanfang Yang, Yongbiao Guan, Xuejun Xia, Yuling Liu. Tumor-targeting intravenous lipid emulsion of paclitaxel: Characteristics, stability, toxicity, and toxicokinetics[J]. Journal of Pharmaceutical Analysis, 2022, 12(6): 901-912. doi: 10.1016/j.jpha.2022.08.002

Citation:

Jun Ye, Lin Li, Jiye Yin, Hongliang Wang, Renjie Li, Yanfang Yang, Yongbiao Guan, Xuejun Xia, Yuling Liu. Tumor-targeting intravenous lipid emulsion of paclitaxel: Characteristics, stability, toxicity, and toxicokinetics[J]. Journal of Pharmaceutical Analysis, 2022, 12(6): 901-912. doi: 10.1016/j.jpha.2022.08.002

Citation:

Jun Ye, Lin Li, Jiye Yin, Hongliang Wang, Renjie Li, Yanfang Yang, Yongbiao Guan, Xuejun Xia, Yuling Liu. Tumor-targeting intravenous lipid emulsion of paclitaxel: Characteristics, stability, toxicity, and toxicokinetics[J]. Journal of Pharmaceutical Analysis, 2022, 12(6): 901-912. doi: 10.1016/j.jpha.2022.08.002

PDF( 2731 KB)

Tumor-targeting intravenous lipid emulsion of paclitaxel: Characteristics, stability, toxicity, and toxicokinetics

doi: 10.1016/j.jpha.2022.08.002

Jun Ye^a,b,
Lin Li^a,b,
Jiye Yin^c,
Hongliang Wang^a,b,
Renjie Li^a,b,
Yanfang Yang^a,b,
Yongbiao Guan^{c
,
,},
Xuejun Xia^{b
,
,},
Yuling Liu^{a
,
,}

a. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China;
b. Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China;
c. National Beijing Center for Drug Safety Evaluation and Research, Beijing Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100850, China

Funds:

This work was financially supported by the National Science and Technology Major Project of China (Grant No.: 2018ZX09711001), Beijing Nova Program (Grant No.: Z211100002121127), Beijing Natural Science Foundation (Grant No.: L212059), Fundamental Research Funds for the Central Universities (Grant No.: 3332021101), and CAMS Innovation Fund for Medical Sciences (CIFMS, Grant No.: 2022-I2M-JB-011).

Received Date: Jun. 09, 2022
Accepted Date: Aug. 17, 2022
Rev Recd Date: Jul. 28, 2022
Publish Date: Dec. 26, 2022

Abstract

Abstract

Lipid nanoemulsions are promising nanodrug delivery carriers that can improve the efficacy and safety of paclitaxel (PTX). However, no intravenous lipid emulsion of PTX has been approved for clinical treatment, and systemic safety profiles have not yet been reported. Here we outline the development of a PTX-loaded tumor-targeting intravenous lipid emulsion (PTX Emul) and describe its characteristics, colloidal stability, and systemic safety profiles in terms of acute toxicity, long-term toxicity, and toxicokinetics. We also compare PTX Emul with conventional PTX injection. Results showed that PTX Emul exhibited an ideal average particle size (approximately 160 nm) with narrow size distribution and robust colloidal stability under different conditions. Hypersensitivity reaction and hemolysis tests revealed that PTX Emul did not induce hypersensitivity reactions and had no hemolytic potential. In addition, where the alleviated systemic toxicity of PTX Emul may be attributed to the altered toxicokinetic characteristics in beagle dogs, including the decreased AUC and increased plasma clearance and volume of distribution, PTX Emul alleviated acute and long-term toxicity as evidenced by the enhanced the median lethal dose and approximate lethal dose, moderate body weight change, decreased bone marrow suppression and organ toxicity compared with those under PTX injection at the same dose. A fundamental understanding of the systemic safety profiles, high tumor-targeting efficiency, and superior antitumor activity in vivo of PTX Emul can provide powerful evidence of its therapeutic potential as a future treatment for breast cancer.
- Nanodrug delivery systems,
- Lipid emulsion,
- Paclitaxel,
- Colloidal Stability,
- Toxicokinetics

FullText(HTML)

References(43)

References

C.M. Spencer, D. Faulds, Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer, Drugs 48 (1994) 794-847

R. Panchagnula, Pharmaceutical aspects of paclitaxel, Int. J. Pharm. 172 (1998) 1-15

E.K. Rowinsky, R.C. Donehower, Paclitaxel (taxol), N. Engl. J. Med. 332 (1995) 1004-1014

J. Xiang, X. Liu, G. Yuan, et al., Nanomedicine from amphiphilizedprodrugs: Concept and clinical translation, Adv. Drug Deliv. Rev. 179 (2021), 114027

J. Gonzalez-Valdivieso, A. Girotti, J. Schneider, et al., Advanced nanomedicine and cancer: challenges and opportunities in clinical translation, Int. J. Pharm. 599 (2021), 120438

Q. Chen, S. Xu, S. Liu, et al., Emerging nanomedicines of paclitaxel for cancer treatment, J. Control. Release 342 (2022) 280-294

H. Li, W.Y. Wei, H. Xu, Drug discovery is an eternal challenge for the biomedical sciences, Acta Mater. Med. 1 (2022) 1-3

X. Zheng, J. Xie, X. Zhang, et al., An overview of polymeric nanomicelles in clinical trials and on the market, Chin. Chem. Lett. 32 (2021) 243-257

A.M. Sofias, M. Dunne, G. Storm, et al., The battle of “nano” paclitaxel, Adv. Drug Deliv. Rev. 122 (2017) 20-30

A. Gupta, H.B. Eral, T.A. Hatton, et al., Nanoemulsions: Formation, properties and applications, Soft Matter 12 (2016) 2826-2841

Y. Singh, J.G. Meher, K. Raval, et al., Nanoemulsion: Concepts, development and applications in drug delivery, J. Control. Release 252 (2017) 28-49

K. Hörmann, A. Zimmer, Drug delivery and drug targeting with parenteral lipid nanoemulsions - a review, J. Control. Release 223 (2016) 85-98

N. Machado, BMH. Bruininks, P. Singh, et al., Complex nanoemulsion for vitamin delivery: Droplet organization and interaction with skin membranes, Nanoscale 14 (2022) 506-514

V.K. Rai, N. Mishra, K.S. Yadav, et al., Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications, J. Control. Release 270 (2018) 203-225

Y. Gao, S. Zuo, L. Li, et al., The length of disulfide bond-containing linkages impacts the oral absorption and antitumor activity of paclitaxel prodrug-loaded nanoemulsions, Nanoscale 13 (2021) 10536-10543

A. Abu-Fayyad, M.M. Kamal, J.L. Carroll, et al., Development and in-vitro characterization of nanoemulsions loaded with paclitaxel/γ-tocotrienol lipid conjugates, Int. J. Pharm. 536 (2018) 146-157

X. Jing, L. Deng, B. Gao, et al., A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel, Nanomedicine 10 (2014) 371-380

H. Bu, X. He, Z. Zhang, et al., A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer, Int. J. Pharm. 471 (2014) 206-213

L.A. Pires, R. Hegg, C.J. Valduga, et al., Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study, Cancer Chemother. Pharmacol. 63 (2009) 281-287

X.-J. Xia, R.-F. Guo, Y.-L. Liu, et al., Formulation, characterization and hypersensitivity evaluation of an intravenous emulsion loaded with a paclitaxel-cholesterol complex, Chem. Pharm. Bull. (Tokyo) 59 (2011) 321-326

J. Ye, Y. Liu, X. Xia, et al., Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors, Oncol. Rep. 36 (2016) 399-409

J. Ye, X. Xia, W. Dong, et al., Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines, Int. J. Nanomedicine 11 (2016) 4125-4140

J. Ye, W. Dong, Y. Yang, et al., Vitamin E-rich nanoemulsion enhances the antitumor efficacy of low-dose paclitaxel by driving Th1 immune response, Pharm. Res. (N. Y.) 34 (2017) 1244-1254

J. Ye, R. Li, Y. Yang, et al., Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations, J. Nanobiotechnology 19 (2021), 199

National Research Council (US) Institute for Laboratory Animal Research, Guide for the Care and Use of Laboratory Animals, National Academies Press (US), Washington D.C., 1996

W. Dong, J. Ye, W. Wang, et al., Self-assembled lecithin/chitosan nanoparticles based on phospholipid complex: a feasible strategy to improve entrapment efficiency and transdermal delivery of poorly lipophilic drug, Int. J. Nanomedicine 15 (2020) 5629-5643

J. Ye, Y. Yang, J. Jin, et al., Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma, Bioact. Mater. 5 (2020) 694-708

Y. Lu, W. Kang, J. Jiang, et al., Study on the stabilization mechanism of crude oil emulsion with an amphiphilic polymer using the β-cyclodextrin inclusion method, RSC Adv. 7 (2017) 8156-8166

Y.-L. Ma, J. Ye, P.-X. Zhang, et al., Comparative study on pharmacokinetics and tissue distribution of a novel microemulsion based on the paclitaxel/L-OH lipid complex and paclitaxel injection in cremophor, Acta Pharm. Sin. 48 (2013) 1698-1704

H.B. Ruttala, T. Ramasamy, B.S. Shin, et al., Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel, Int. J. Pharm. 519 (2017) 11-21

H.B. Ruttala, Y.T. Ko, Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy, Pharm. Res. (N. Y.) 32 (2015) 1002-1016

N. Ghavidel, P. Fatehi, Pickering/non-Pickering emulsions of nanostructured sulfonated lignin derivatives, ChemSusChem 13 (2020) 4567-4578

J. Desai, H. Thakkar, Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation, Colloids Surf. B Biointerfaces 175 (2019) 143-149

R. Song, F. Yan, M. Cheng, et al., Ultrasound-assisted preparation of exopolysaccharide/nystatin nanoemulsion for treatment of vulvovaginal candidiasis, Int. J. Nanomedicine 15 (2020) 2027-2044

M.L. Manca, P. Matricardi, C. Cencetti, et al., Combination of argan oil and phospholipids for the development of an effective liposome-like formulation able to improve skin hydration and allantoin dermal delivery, Int. J. Pharm. 505 (2016) 204-211

M.P.L. Sentis, G. Brambilla, V. Fessard, et al., Simultaneous screening of the stability and dosimetry of nanoparticles dispersions for in vitro toxicological studies with static multiple light scattering technique, Toxicol. Vitro 69 (2020), 104972

C.R. Hong, G.W. Lee, H.D. Paik, et al., Influence of lysolecithin and Tween 80 on the colloidal stability of branched chain amino acids in a nanosuspension system, Food Chem. 221 (2017) 606-612

A.K. Jain, S. Thareja, In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery, Artif. Cells Nanomed. Biotechnol. 47 (2019) 524-539

F.-C. Liu, H.-P. Yu, C.-Y. Lin, et al., Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge, J. Nanobiotechnology 16 (2018), 35

S. Bhattacharjee, DLS and zeta potential - what they are and what they are not? J. Control. Release 235 (2016) 337-351

E.K. Rowinsky, E.A. Eisenhauer, V. Chaudhry, et al., Clinical toxicities encountered with paclitaxel (taxol), Semin. Oncol. 20 (1993) 1-15

P. Vishnu, V. Roy, Safety and efficacy of nab-paclitaxel in thetreatment of patients with breast cancer, Breast Cancer 5 (2011) 53-65

N. Desai, V. Trieu, Z.W. Yao, et al., Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin. Cancer Res. 12 (2006) 1317-1324

Relative Articles

Supplements(0)

Cited By

Proportional views